Subscription and demo access


 
About Interfax
Press Releases
Products & Services
Contact Us
Customer Login
 


Headlines
 

04/02 05:00   Russia political and economic calendar: April 2
 
04/01 22:05   OSCE monitors say fighting continued in parts of east Ukraine on Mar 31
 
04/01 21:59   Prosecutor General's Office sees no reasons to dispute extension of Savchenko's confinement (Part 2)
 
04/01 21:46   LPR negotiator praises Contact Group videoconference
 
04/01 21:29   Peskov redirects question about incident with Russian aircraft in Yemen to Foreign Ministry
 
04/01 21:28   Transdniestria denies firing on men trying to cross border
 
04/01 21:14   SBU reports detention of 3 people who confessed to perpetrating terror attacks in Odesa
 
04/01 20:58   Prosecutor General's Office sees no reasons to dispute extension of Savchenko's confinement
 
04/01 20:47   Kremlin denies knowing if Russia, ex-Yukos shareholders holding claim settlement talks
 
04/01 20:09   Key suspect in Nemtsov murder case claims to have been abducted for two days (Part 3)
 




 

Interfax.com  |  Interfax news  |  Pharmstandard, Millhouse close deal to acquire...


News headlines


July 25, 2014 09:25

Pharmstandard, Millhouse close deal to acquire stakes in Biocad Holding

MOSCOW. July 25 (Interfax) - Pharmstandard (MOEX: PHST), a major Russian drug maker, and Millhouse have completed individual acquisitions of shares in Biocad Holding Ltd., the principal shareholder of St. Petersburg-based biotech company CJSC Biocad, the companies said in a joint statement.

Pharmstandard acquired a 20% stake in Biocad Holding Ltd., while a company affiliated with Millhouse acquired 50%.

Pharmstandard financed the acquisition with its own money, the press release states.

Biocad CEO and founder Dmitry Morozov will retain a 30% stake in Biocad Holding Ltd and will continue to run the company with his management team, the statement said.

Biocad develops, manufactures and promotes its own and generic drugs to treat illnesses in the areas of urology, gynecology, dermatovenereology, oncology and hematology, as well as autoimmune and infectious diseases. The company has a line of 14 drugs.

"Millhouse and Pharmstandard have a successful track record of working together to develop leaders in the pharmaceutical market. The companies previously cooperated on the acquisitions of ICN Pharmaceuticals, Inc. and CJSC Masterlek, and on Pharmstandard's initial public offering," the press release said.

It was reported earlier that in this deal the companies would buy the stake of Gazprombank (MOEX: GZPR), which acquired a controlling stake in the pharmaceutical company in 2011 for about $250 million-$300 million, as well as part of the stake held by company management.

RMG senior analyst Ksenia Arutyunova valued all of Biocad at $1 billion. Therefore, the stakes acquired by Pharmstandard and Millhouse are worth $200 million and $500 million respectively.

Millhouse is acting as a financial investor, who will divest the stake at some point, Arutyunova said, adding that this stake could be bought by Pharmstandard.

Biocad currently sells its products in Russia and other CIS countries. The company has offices in Ukraine, Belarus, Brazil, China, India and the United States. Biocad is also setting up production of drugs based on monoclonal antibodies in Brazil.

Biocad has two factories in Russia - in the Moscow Region and in the St. Petersburg special economic zone. The company had revenue of 3 billion rubles in 2013.

It was reported earlier that U.S. drug makers Pfizer and Amgen were interested in buying Biocad. The company was valued at $0.75 billion-$1 billion.

Vp of

(Our editorial staff can be reached at eng.editors@interfax.ru)

/Interfax/
 Subscription
You can access a demo version of, receive more information about or subscribe to Interfax publications by filling in and returning the form below. We also have dozens of reports in the Russian language, please indicate if you are interested.
Title:


Phone:


E-mail:


First name:


Company:


Country:
Last name:


Division:


City:
Products:
Central Asia & Caucasus Business Weekly
Central Asia General Newswire
Global Gas Analytics
Global Natural Gas Daily
Interfax Via Bloomberg Terminal
Kazakhstan General Newswire
Kazakhstan Mining Weekly
Kazakhstan Oil & Gas Weekly
Russia & CIS Announcements
Russia & CIS Banking and Finance Weekly
Russia & CIS Business and Financial Daily
Russia & CIS Business and Financial Newswire
Russia & CIS Business and Investment Weekly
Russia & CIS Business Law Weekly
Russia & CIS Business news
Russia & CIS Defense Industry Weekly
Russia & CIS Diplomatic Panorama
Russia & CIS Energy Daily
Russia & CIS Energy Newswire
Russia & CIS Events Calendar
Russia & CIS Food and Agriculture Weekly
Russia & CIS General Newswire
Russia & CIS Headline News
Russia & CIS Insurance Weekly
Russia & CIS IT and Telecom Weekly
Russia & CIS Metals and Mining Weekly
Russia & CIS Military Daily
Russia & CIS Military Newswire
Russia & CIS Military Weekly
Russia & CIS Oil and Gas Weekly
Russia & CIS Presidential Bulletin
Russia & CIS Statistics Weekly
Russia Health & Pharmaceuticals
Russia Market Roundup
Russia Press Review
Ukraine Business Daily
Ukraine Business Weekly
Ukraine General Newswire
Please enter the digits from picture in the box below:

April 02, 2015
 
05:00
Russia political and economic calendar: April 2
 
April 01, 2015
 
22:05
OSCE monitors say fighting continued in parts of east Ukraine on Mar 31
 
21:59
Prosecutor General's Office sees no reasons to dispute extension of Savchenko's confinement (Part 2)
 
21:46
LPR negotiator praises Contact Group videoconference
 
21:29
 
21:28
Transdniestria denies firing on men trying to cross border
 
21:14
SBU reports detention of 3 people who confessed to perpetrating terror attacks in Odesa
 
20:58
Prosecutor General's Office sees no reasons to dispute extension of Savchenko's confinement
 
20:47
Kremlin denies knowing if Russia, ex-Yukos shareholders holding claim settlement talks
 
20:09
Key suspect in Nemtsov murder case claims to have been abducted for two days (Part 3)
 
20:02
Roshen factory in Russia, research firm accused of fraudulent tax rebate - spokesman
 
20:02
Investigation to check claims of suspected Nemtsov murderer concerning ill-treatment (Part 2)
 
20:00
Symonenko has no official information from SBU about summons to interrogation
 
20:00
Ruble gains against dollar, euro on Wednesday amid rising oil prices
 
 more headlines 



Interviews
 

.
Russian Foreign Minister Sergei Lavrov has given an interview with Interfax, in which he summed up the results of this foreign policy year and spoke about the priorities of Russian diplomacy in 2015

more
.
.
Germanys E.ON is spinning its Russian business off to a "New Company" which will be transferred to the companys shareholders, with plans to list it in 2016. Apart from the Russia business, the new company will receive all of E.ONs conventional energy assets. E.ON itself will focus on renewable energy and innovation. Johannes Teyssen, E.ONs CEO, told Interfax in an interview of the logic behind the decision and its implications for the concerns Russian subsidiary OJSC E.ON Russia.

more
.
.
Australian Ambassador to Russia Paul Myler has given an interview to Interfax ahead of the G20 summit in Brisbane in which he speaks about the MH17 crash, the reasons for joining the West‘s sanctions against Russia and explained why Australia expects changes in Russia‘s food policy by March 2015.

more

 
  
 ©   1991—2015   Interfax Information Service. All rights reserved.
contact information   |   Interfax offices   |   made by web.finmarket

News and other data on this site are provided for information purposes only, and are not intended for republication or redistribution. Republication or redistribution of Interfax content, including by framing or similar means, is expressly prohibited without the prior written consent of Interfax.

Browse other Interfax sites:  Interfax.ru   |   IFX.RU   |   Interfax Group   Rambler's Top100